Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.55 +0.02 (+0.10%)
Streaming Delayed Price Updated: 3:04 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
3 Blue-Chip Stocks Set to Triple Soon
Blue-chip stocks are great additions to a portfolio. If you're looking for consistent returns, check out these blue-chip stocks to buy. 
Via InvestorPlace
Pfizer Unusual Options Activity
Via Benzinga
Cómo esta estrella del béisbol toma la iniciativa cuando se trata de neumonía neumocócica
(BPT) - El jugador profesional de béisbol JD Martínez presenta un mayor riesgo de neumonía neumocócica porque tiene asma y no quiere dejar que eso decida si va a seguir jugando, o no. Por si no está... 
Via Brandpoint
3 High-Yield Dividend Stocks I'm Buying Hand Over Fist
There's a lot to like with these great stocks. 
Via The Motley Fool
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With Less Than $100 Right Now
High yields and a strong chance for steady payout raises in the years ahead make these great stocks to buy now. 
Via The Motley Fool
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Is This a Setback for Moderna?
Moderna's shares slipped after the company announced the delay. 
Via The Motley Fool
Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?
Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year. 
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga
7 Value Stocks to Buy and Hold for a Decade of Dominance
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities. 
Via InvestorPlace
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths... 
Via The Motley Fool
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
It depends on what your goals, objectives, and risk tolerances are. 
Via Talk Markets
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Investors might be remiss to overlook these stocks. 
Via The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc has agreed to pay up to $250 million. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform. 
Via Benzinga
Exposures COVID-19
7 Cheap Value Stocks to Buy Now: May 2024
Worried about a potential market correction? These seven cheap value stocks are bargains today regardless of the broader economic climate. 
Via InvestorPlace
3 No-Brainer Stocks to Buy With $500 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in game-changing companies. 
Via The Motley Fool
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
These healthcare stocks offer completely different approaches to long-term investment gains. 
Via The Motley Fool
Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
Pfizer seeks to expands its reach with 'Pfizer for All,' offering direct-to-consumer medical services, including COVID treatments & telehealth. 
Via Benzinga
Exposures COVID-19
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation. 
Via Benzinga
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
Generis Welcomes Max Kelleher as New Chief Executive Officer
LONDON - May 14, 2024 - PRLog -- Generis, creator of the cloud data, content, and business process management platform CARA™, today announced that Max Kelleher will be stepping into the role of Chief... 
Via PRLog
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.